Sign up to save your podcasts
Or
Share Eligibility for Anti-Amyloid Treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Eligibility for Anti-Amyloid Treatment
Dr. Gregg Day talks with Dr. Vijay Ramanan about the clinical trial eligibility criteria for lecanemab treatment for participants with early Alzheimer disease and the generalizability of anti-amyloid treatment.
Read the related article in Neurology.
Visit NPub.org/Podcast for associated article links.
View all episodes
By American Academy of Neurology
4.7
283283 ratings
Dr. Gregg Day talks with Dr. Vijay Ramanan about the clinical trial eligibility criteria for lecanemab treatment for participants with early Alzheimer disease and the generalizability of anti-amyloid treatment.
Read the related article in Neurology.
Visit NPub.org/Podcast for associated article links.
More shows like Neurology® Podcast
View all
NEJM This Week
320 Listeners
JAMA Clinical Reviews
497 Listeners
Practical Neurology Podcast
52 Listeners
Mayo Clinic Talks
288 Listeners
The Curbsiders Internal Medicine Podcast
3,342 Listeners
JAMA Neurology Author Interviews
13 Listeners
Core IM | Internal Medicine Podcast
1,153 Listeners
Neurology Today in 5
21 Listeners
Annals On Call Podcast
194 Listeners
Navigating Neuropsychology
361 Listeners
The Clinical Problem Solvers
513 Listeners
Neurology Minute
133 Listeners
Neurology Exam Prep Podcast
180 Listeners
The Curious Clinicians
370 Listeners
Continuum Audio
79 Listeners